• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Surgical vs Pharmaceutical Abortion: Comparing the Risks for Serious Adverse Events

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Liu et al. (Annals of Internal Medicine, 2023) compared short-term risk for adverse outcomes after early mifepristone–misoprostol induced abortion (IA) vs procedural IA

METHODS:

  • Population-based cohort study
  • Population
    • Women who had first-trimester IA
  • Exposure
    • Comparison 1
      • Pharmaceutical IA: Outpatient mifepristone–misoprostol
      • Procedural IA: Performed at ≤14 weeks in nonhospital outpatient clinics
    • Comparison 2
      • Pharmaceutical IA
      • Procedural IA performed at ≤9 weeks at ambulatory hospital-based clinics
  • Study design
    • Confounding between exposure groups was included in estimated risk calculations
  • Primary outcomes
    • Composite of any serious adverse events within 42 days after IA: Severe maternal morbidity | End-organ damage | ICU admission | Death
    • Broader composite outcome: Any serious adverse event | Hemorrhage | Retained products of conception | Infection | Transfusion

RESULTS:

  • Pharmaceutical: 39,856 women | Procedural, nonhospital: 65,176 | Procedural, hospital: 8861
    • Mean age at IA: 29 (SD, 7) years
    • Primigravid: 33%
    • Resided in rural areas: 6% | Resided in low-income neighborhoods: 25%

Comparison 1

  • The risk of serious adverse events was higher in the pharmaceutical IA group
    • Pharmaceutical: 3.3 per 1000
    • Procedural, ≤14 weeks, nonhospital: 1.8 per 1000
    • Relative risk (RR) 1.87 (95% CI, 1.44 to 2.43)
    • Absolute risk difference 1.5 per 1000 (95% CI, 0.9 to 2.2)
  • Risk of any adverse event (broader outcome) were also higher in the pharmaceutical group
    • Pharmaceutical: 28.9 per 1000
    • Procedural, ≤14 weeks, nonhospital: 12.4 per 1000
    • RR 2.33 (95% CI, 2.11 to 2.57)
    • Absolute risk difference 16.5 per 1000 (95% CI, 14.5 to 18.4)

Comparison 2

  • There was no difference in risk of serious adverse events between the groups
    • Pharmaceutical: 3.4 per 1000
    • Procedural, ≤9 weeks, hospital: 3.3 per 1000
    • RR 1.04 (95% CI, 0.61 to 1.78)
  • Risk of any adverse event was slightly higher in the pharmaceutical group
    • Pharmaceutical: 31.2 per 1000
    • Procedural, ≤9 weeks, hospital: 24.9 per 1000
    • RR 1.25 (95% CI, 1.04 to 1.51)

CONCLUSION:

  • Serious adverse events are rare for induced abortions, but do occur more frequently after pharmaceutical vs procedural approach
  • This risk is highest for less serious adverse events

The authors state

The current findings underscore the apparent overall short-term safety of accessible first-trimester IA, especially for SAEs, which are very rare

In conclusion, although short-term adverse events occur more often after mifepristone–misoprostol IA than procedural IA, the risk for serious adverse outcomes is very small

Learn More – Primary Sources:

Short-Term Adverse Outcomes After Mifepristone–Misoprostol Versus Procedural Induced Abortion: A Population-Based Propensity-Weighted Study

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Pregabalin: A Prophylactic Treatment to Reduce Medication Abortion Pain?
Does Gabapentin Reduce Pain Following Surgical Abortion?
Does Abortion Increase Risk of Antidepressant Use

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site